The Samsung Biologics PolyPeptide deal, an all-cash transaction worth approximately CHF 1.46 billion (US$1.8 billion), represents more than a conventional pharmaceutical acquisition....Read More
For decades, the U.S. Food and Drug Administration’s (FDA) Pharmacy Compounding Advisory Committee (PCAC) operated largely outside the public spotlight....Read More
Artificial intelligence has rapidly evolved from an emerging technology to a core component of modern healthcare. Today, AI-enabled software helps radiologists...Read More